Dynavax Technologies Corporation (DVAX) Shares are Down -8.06%

Dynavax Technologies Corporation (DVAX) : During the past 4 weeks, traders have been relatively bearish on Dynavax Technologies Corporation (DVAX), hence the stock is down -3.33% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.21% relative to the S&P 500. The 4-week change in the price of the stock is -3.85% and the stock has fallen -8.06% in the past 1 week.

The stock has recorded a 20-day Moving Average of 12.39% and the 50-Day Moving Average is 26.68%.The 200 Day SMA reached 40.86%


Dynavax Technologies Corporation (NASDAQ:DVAX): After opening at $10.34, the stock dipped to an intraday low of $10.11 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $10.62 and the buying power remained strong till the end. The stock closed at $10.49 for the day, a gain of 1.55% for the day session. The total traded volume was 1,303,825. The stocks close on the previous trading day was $10.49.

Dynavax Technologies Corporation (DVAX) : The most positive equity analysts on Dynavax Technologies Corporation (DVAX) expects the shares to touch $45, whereas, the least positive believes that the stock will trade at $17 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $31.5 with an expected fluctuation of $15.61 from the mean.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *